chrisvoncsefalvay/vaers-outcomes huggingface dataset:
6 hrs after the 3rd shot I developed finger locking and swelling in the fingers in my left hand; 6 hrs after the 3rd shot I developed finger locking and swelling in the fingers in my left hand; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP and Physician). The reporter is the patient.  A 73 year-old male patient received bnt162b2 (BNT162B2), administered in arm left, administration date 14Oct2021 16:30 (Lot number: FF2h93) at the age of 72 years as dose 3 (booster), single for covid-19 immunisation. Relevant medical history included: "High Blood Pressure" (ongoing); "L knee arthritis" (ongoing); "Obesity" (ongoing); "erectile dysfunction" (ongoing); "HTN" (ongoing); "HLD" (ongoing); "Urinary Urgency" (ongoing). Concomitant medication(s) included: FLU taken for influenza immunisation; OXYBUTYNIN taken for micturition urgency (ongoing); AMLODIPINE taken for hypertension (ongoing); LISINOPRIL taken for hypertension (ongoing); SILDENAFIL taken for erectile dysfunction (ongoing). Past drug history included: Allergy: statins, reaction(s): "Allergy: statins"; Allergy: erythromycin, reaction(s): "Allergy: Erythromycin". Vaccination history included: Bnt162b2 (Dose Number: 2, Batch/Lot No: EN6 (or G) 208, Location of injection: Arm Left), administration date: 08Apr2021, when the patient was 72 years old, for COVID-19 Immunization, reaction(s): "had finger joint swelling and locking", "had finger joint swelling and locking"; Bnt162b2 (Dose Number: 1, Batch/Lot No: EWG150, Location of injection: Arm Left), administration date: 18Mar2021, when the patient was 72 years old, for COVID-19 Immunization, reaction(s): "had finger joint swelling and locking", "had finger joint swelling and locking". The following information was reported: PERIPHERAL SWELLING (non-serious), TRIGGER FINGER (non-serious) all with onset 15Oct2021 02:00, outcome "recovered" (15Oct2021 11:00) and all described as "6 hrs after the 3rd shot I developed finger locking and swelling in the fingers in my left hand". Therapeutic measures were not taken as a result of peripheral swelling, trigger finger.  Additional information: The swelling and finger locking went away approximately 12 to 18 hours later and returned to pre-shot condition. No relevant Tests performed. Prior to vaccination, patient was not diagnosed with COVID-19. Since the vaccination, patient not been tested for COVID-19. List of any other medications the patient received within 2 weeks of vaccination was Blood Pressure Meds. No specific Relevant Test for thromboembolic events with thrombocytopenia was done. Patient reported swelling in fingers L hand, locking of L 5th and 2nd digit. He was not seen/ examined for reported symptoms.   No follow-up attempts are possible. No further information is expected.
This spontaneous report has been received from a nurse practitioner regarding a patient of unknown age and gender. The patient's concurrent condition, medical history and concomitant medications were not reported. On an unknown date, the patient was vaccinated (Oka/Merck) VARIVAX dose 1, (dose, lot # and expiry date unknown) On 03-MAR-2015, the patient received improperly stored (Oka/Merck) VARIVAX dose 2, from lot # K007982 (dose, vaccination site, route, expiry date unknown). No adverse effects were reported. The reporter stated that inconsistencies in storage temperature were identified on extensive review of records. The reporter stated that vaccine was not thawed. The nurse practitioner reported that there was insufficient data to provided 100 percent assurance on vaccine stability. This is one of several reports received from the same reporter. Additional information has been requested.
About 7 hours after vaccination I received a bad burning itchy cough. Lasted for minutes each time. Could not stop coughing. Then it turned into  cold like symptoms with running nose and low grade fevers.  The cough continued to bother me and I started experiencing a mucus that was thin at first?. One week later I am experiencing chest pressure and breathing issues on the right side, difficulty to breathe and yellow congestion with the cough. I was absolutely in great shape before. Don?t understand so I went to urgent care after my doctor didn?t want to see me in the office.
severe pain in chest; Heart issues; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP).  A patient (no qualifiers provided) received bnt162b2 (BNT162B2) (Batch/Lot number: unknown) as dose number unknown, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: ANGINA PECTORIS (medically significant), outcome "unknown", described as "severe pain in chest"; CARDIAC DISORDER (medically significant), outcome "unknown", described as "Heart issues".  The lot number for bnt162b2 was not provided and will be requested during follow up.
Information has been received a wholesale representative and a nurse concerning a male who on an unspecified date was vaccinated with Pneumovax 23 (lot # 655290/0959F). Subsequently the patient experienced pain, soreness to touch, redness, warmth, and swelling in the injection site arm. Unspecified medical attention was sought. At the time of this report, the outcome of the events was unknown. Additional information has been requested.
Mild symptoms - sore throat, cough, sinus congestion. Home tested positive on 6/30/22. Paxlovid taken for 5 days. 6-30-22 - 7/5/22 Home test negative on 7-5-22. Symptom free. Home test positive on 7/8/22. No symptoms. Developed mild symptoms on 7/10/22.   Symptoms resolved by 7/18/22. Home tested negative on 7-20-22
Patient received DTaP and MENACTRA on left deltoid 2 days prior developed redness 8cm area and painful no fever treated with CEPHALEXIN for presumptive cellulitis.
started getting rash / bumps on feet 5 days after vaccine; following morning (6 days after vaccaine) started to feel more on legs / hands
This case was reported in a literature article and described the occurrence of respiratory failure in a infant subject who received Rotavirus vaccine for prophylaxis. Concurrent medical conditions included HIV infection. On an unknown date, unknown after receiving Rotavirus vaccine, the subject developed respiratory failure. Serious criteria included death and GSK medically significant. Additional event(s) included pneumonia with serious criteria of GSK medically significant. The outcome of respiratory failure was fatal. The outcome(s) of the additional event(s) included pneumonia (unknown). The reported cause of death was respiratory failure. The investigator considered that there was a reasonable possibility that the respiratory failure and pneumonia may have been caused by Rotavirus vaccine. Additional information was provided. This case was reported in a literature article and described the occurrence of pneumonia and respiratory failure in an infant of unspecified age and gender who was vaccinated with unspecified rotavirus vaccine (manufacturer unknown) for prophylaxis. This case corresponds to table 1 reported in this literature article. The patient was part of the study that characterize adverse events (AE) after rotavirus (RV) in infants with immunocompromising conditions (IC) reported to the Vaccine Adverse Event Reporting System (VAERS) from February 2006 to December 2015. The patient had human immunodeficiency virus (HIV) infection. No information on patient's medical or family history or concomitant medication were provided. On an unspecified date, the patient received unspecified rotavirus virus vaccine (administration route and site unspecified, dosage unknown; batch number not provided). The age of vaccination was not provided. On an unspecified date, an unknown period after vaccination, the patient developed pneumonia. On an unspecified date, the patient died. The cause of death was respiratory failure. It was unknown if an autopsy was performed. This case has been considered as serious due to death. The treatment was unknown. The author stated and concluded, "Adverse event (AE) after RV in immunocompromised infants are rarely reported to VAERS, but most are clinically serious events. Additional data would be helpful in assessing the safety of RV in non-SCID IC including in-utero exposure to monoclonal antibodies MAB". This is 1 of the 11 valid cases reported in this literature article. The article corresponding to this case is not available for submission due to copyright restriction. Reported Cause(s) of Death: Respiratory failure.
Pt recvd vax 14AUG92 & exp h/a for 3 days & flu-like sx; did not receive treatment; sx resolved;
swelling in his/her eye; redness around the corner of the eye; when he/she lifted the eyelid up there was like red vein visible; very bad like strong pain in the eye; This is a spontaneous report from a contactable consumer (patient). A patient of unspecified age and gender received the second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number EW0158), via an unspecified route of administration administered in the left arm on 14Apr2021 (also reported as "14Feb2021") at a single dose for covid-19 immunization. The patient's medical history and concomitant medications were not reported. The patient previously received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number unknown) on an unspecified date for covid-19 immunization. The patient got the second Pfizer vaccine on Wednesday (14Apr2021) and a day later on 15Apr2021, the patient had swelling in his/her eye, redness around the corner of the eye and then when he/she lifted the eyelid up there was like red vein visible and there was very bad like strong pain in the eye. The patient stated that he/she waited a couple of days just to see (observe) and it did last for a couple of days, but it didn't completely go away. So, the patient called the eye doctor and asked what it might be, and the doctor thought it was like a hemorrhage like a busted blood vessel in the eye - not confirmed. The patient thought it has to do with the vaccination because it appeared a day after getting the vaccine. The eye doctor questioned if the patient has lifted anything heavy or had done anything out of the ordinary that might have caused that to happen to his/her eye and the patient answered "no". The patient was taking it very easy because after the vaccination, he/she was told that one can have some side effects. Hence, the patient wanted to find out if anybody else has reported a similar side effect. The patient added that he/she had not taken anything prior to the vaccination; and he/she did not take any treatment for the reported adverse events. The outcome of the adverse events was unknown.  Information about the lot/batch number has been requested.
dizziness, nausea, sweatiness, feeling high, transient lt chest pain;sx persisted @ least 4hr but are improving gradually;throat felt swollen;nl exam;no hives or wheezing;had hematoma @ site;
Chunks of hair have fallen out of my head since getting my vaccine. However, I didn't notice anything was amiss until early June when I was flipping my hair in a way that exposed one of them. The other patch was discovered by a nurse practitioner when I went to see her about the first bald patch on June 9, 2021 (the appointment was also to address musculoskeletal widespread pain and fatigue). In my patient notes, she wrote "patches on head without erythema, edema, warmth. Hair follicles visible, no scarring evident. Mild thinning of hair in 0.5cm border of each area." These patches look similar to pictures of patients with alopecia areata, which is not a condition I've ever been diagnosed with. The nurse practitioner referred me to a dermatologist, whom I will be seeing on July 2, 2021.
Patient called the clinic and stated that on the 30th of October she had pain at the injection site, red sleepy eyes, red cheeks, ticklish cough, chills, Temp 102 and extreme fatigue. Adversely affected her brain, numb feet and a few seconds she couldn't recall but she fell from the toilet seat. She looked at her hands the next day and they looked unfamiliar to her. Took days for normal brain function to return.
Severe pain in arm that was injected. Fever. Muscle aches. Headache. General feeling of fatigue.
I woke up at 2:00 in am on 12th with chills and sore left arm. When I got up at about 09:00 am on 12th, I had a temp of 100.7. Still had the sore arm. The temperature ranged from 100 to 100.7 for the next couple of days - so on 14th it was done. I had fatigue too and that lasted until about the 14th. My sore arm lasted until the 17th or 18th. I called my Dr and he thought it was due to vaccination. I had had the COVID virus back in November 2020.
I developed a sore throat that was followed by body aches, chills, and a dry cough. I also had a headache. I went to the doctor, and they completed a PCR COVID-19 Test on October 31, 2022, and it was positive. The doctor prescribed Paxlovid. My symptoms have improved. I still have congestion and sore throat along with fatigue. The body aches and headache have improved.
Tenderness  at the back of his left ear; Inflammation at the back of his left ear; Rash at the top of his head; Fatigue; Inappropriate schedule of vaccine administerd; This spontaneous case was reported by a consumer and describes the occurrence of TENDERNESS (left ear), INFLAMMATION, RASH (the top of his head), FATIGUE, and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION in a 52-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   In February 2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 22-Oct-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 22-Oct-2021, the patient experienced TENDERNESS, INFLAMMATION, RASH (Rash at the top of his head), FATIGUE (Fatigue) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION. On 22-Oct-2021, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Inappropriate schedule of vaccine administerd) had resolved. At the time of the report, TENDERNESS, INFLAMMATION, RASH, and FATIGUE outcome was unknown.            No concomitant medication was mentioned. No treatment medication was mentioned.
Infant developed a rash all over his body 2 hrs after he received his immunization. The rash lasted 5 days. Mother took the baby to the ER 2 days after rash started. During this time he developed a fever of 102 deg F. for a brief period.
Narrative: 7/28-Covid positive; reports vomiting, dizziness, nausea, cough 7/31- also reports loss of taste/smell, myalgias, dyspnea, myalgia, headache, fatigue 8/4- worsening cough/congestion, went to ED 8//8- symptoms improving, occasional fatigue and myalgia
Confusion, Dizziness, Tachypnea, HYPERtension, Tachycardia, Shaking, 190/116, HR 130 Narrative:
The day after receiving the COVID injection I started experiencing shooting pain and tingling in left arm, then a day or two later experienced a burning sensation in lower left arm. The pain in left arm significantly increased over the next few days and on Friday evening developed blisters in the palm of left hand. On Saturday, March 6, 2020 was diagnosed with Shingles potentially caused from the COVID vaccine.
Will I experience hair loss because of the vaccine; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of ALOPECIA (Will I experience hair loss because of the vaccine) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. Unknown) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1. On an unknown date, the patient experienced ALOPECIA (Will I experience hair loss because of the vaccine). At the time of the report, ALOPECIA (Will I experience hair loss because of the vaccine) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medications were reported. Treatment medications were not provided by the reporter.   Reporter did not allow further contact
Received first two Pfizer covid 19 vaccine doses in January, 2021, 3 weeks apart, with no adverse event. Received 3rd dose (booster) of Pfizer covid 19 vaccine in right arm on Thursday, 10/21/2021. By Saturday, 10/23/2021  loss of all function in right hand/wrist. X ray taken and normal. No swelling. No pain. Some physical therapy and wearing a hand/wrist brace part time. After 2 weeks, no change. Adverse event still in effect.
Information has been received from a registered nurse referring to a patient of unknown age and gender. There was no pertinent medical history, concomitant medication or drug allergies/drug reactions reported. On 02-SEP-2015, the patient was vaccinated with ZOSTAVAX (0.65 ml, Lot #L016284, expiration date: 07-AUG-2016), which was improperly stored for 20 days. The outcome was unknown. This is one of several reports received from the same reporter. Additional information has been requested.
Normal arm discomfort the first week which progressed to shoulder/upper arm pain with movement, sharp when moving across the body, aching after use.
This case was reported by a pharmacist via call center representative and described the occurrence of adverse reaction in a female patient who received Hepatitis B vaccine for prophylaxis. On an unknown date, the patient received Hepatitis B vaccine. On an unknown date, unknown after receiving Hepatitis B vaccine, the patient experienced adverse reaction. On an unknown date, the outcome of the adverse reaction was unknown. It was unknown if the reporter considered the adverse reaction to be related to Hepatitis B vaccine. Additional details were provided as follows: The age at vaccination was not reported. The healthcare professional (HCP) reported that patient had a severe reaction with Hepatitis B vaccine. The HCP was not sure about the manufacturer of the vaccine and did not know what type of reaction the patient had. The HCP did not have any information as a note was left for her from one of her colleagues.
pt had tested positive for COVID on 8/19/21; admitted to hosp with COVID pneumonia and hypoxia; treated with O2 supplementation, remdesivir, dexamethasone; DNR/active treatment status; developed fever; blood cultures grew pseudomonas; treated with ABX; required intubation; pt's condition worsened and she passed away
ONE OF 3 PTS EXP INJECTION SITE REACTION (ERYTHEMA, SWELLING, TENDERNESS AND HOT TO TOUCH) WITHIN 24 HRS AFTER IMMUN, UNABLE TO WALK, TREATED W TYLENOL  AND ICE PACKS AT SOI
The two nights following the vaccine resulted in low fever while sleeping and some whimpering. He attended school the next day (Wednesday) but stayed home Thursday and Friday due to a congested cough that 3 family members had. patient started limping on Thursday afternoon following a very restful day. He complained of L ankle pain.  Friday was fairly normal without complaints until the evening before bed. Then he woke with significant pain during the night. He slept until 10:00am the next morning and had a typical day helping with yard work and relaxing. He again complained of pain in the afternoon and upon examination had a circular, oblong ring shaped rash on posterior L ankle. He woke again that night in pain. Sunday was better in the morning but symptoms worsened earlier in the day, with another circular bruise like rash seen on medial aspect of R foot. He was in significant pain. Also noted swelling in knees and complaints of pain L>R .Stiffness, limping, point tenderness and sensitivity all present at rash sites. Symptoms worsen as the day goes on. Sunday night he slept through the night after having ibuprofen.  He attended school Monday and then saw doctor at 1:30. Rash had worsened. Again worse at 8pm. Applied aquaphor and gave ibuprofen. Limping and stiffness when going to bed with moderate pain.
Patient came in for second COVID vaccine shot, he previously did get Moderna for first dose and on 06/15/21 he was given Pfizer Vaccine at 2:52 PM. Patient did come in during our regular COVID Vaccine walk-in schedule and was mistaken for Pfizer Vaccine.
0840 - Vaccines given. 0842 - pt. c/o nausea & dizziness. Pallor noted to face. Pt taken to sit down & given granola bar & H2O. Pt. remained sitting. 0847 - pt. c/o dizziness, but feeling slightly better. 0859 - pt. feeling better, symptoms resolved. Pt gone home with mom.
doses of improperly stored MMR II were administered to 9 patients on  unspecified dates; No additional adverse symptoms reported; This spontaneous report has been received from an officer manager, referring to a patient of unknown gender and age. Information about the patient's pertinent medical history, concurrent conditions, concomitant medications and, previous drugs reactions or allergies were not provided by the reporter.  On an unknown date, the patient was vaccinated with an improperly stored (product storage error) measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II), (therapy type: Digital Data Logger), lot number S006051, and expiration date 27-FEB-2021 for prophylaxis. Details about strength, dose, dose number, route of administration, and anatomical location were not provided. It was unknown if the sterile diluent (DILUENT MRK) (lot number and expiration date were unknown by the reporter) used for reconstitution of the vaccine, was stored at proper temperature.  The highest temperature was above 47 degree Fahrenheit (°F) (53 F), for a timeframe of 17 hours, with no previous temperature excursion. The call was due to the digital data logger.  No additional adverse symptoms were reported.  This case is one of several cases from the same reporter.; Sender's Comments:  2001USA005521: 2001USA005522: 2001USA005523: 2001USA005524: 2001USA005525: 2001USA005519: 2001USA005518: 2001USA005516:
It was reported in a published article, titled as stated above, that a 21 month old female with stage IV neuroblastoma, who was vaccinated with a dose of Varivax (Oka/Merck). One week later, chemotherapy (unspecified) was initiated. Approximately 5 weeks following vaccination with Varivax (Oka/Merck) the patient had a first appearance of skin lesions and was diagnosed with disseminated varicella-zoster infection. Despite acyclovir therapy, her varicella persisted, which raised concern for resistance. Polymerase chain reaction (PCR) of the virus isolated from the culture of a skin lesion was used to determine the origin of the varicella virus. Anti-viral resistance was determined by plaque assay and further elucidated by viral thymidine kinase enzymatic analysis. Polymerase chain reaction (PCR) of the virus isolated from the culture of a skin lesion was determined to be consistent with the Oka strain of the virus. In-vitro sensitivity analysis revelaed high-level resistance to acyclovir. Further characterized of the isolated strain confirmed a mutation of the viral thymidine kinase (TK) gene whose product did not exhibit detectable enzymatic activity. The patient was ultimately treated with foscarnet but did not demonstrate full resolution of the varicella until cessation of cytotoxic chemotherapy. Three months after cessation of initial chemotherapy, the patient experienced relapse of the neuroblastoma but was ultimately able to undergo autologous stem cell transplantation without varicella reactivation. Upon internal review, the patient's neuroblastoma was considered to be an other important medical event. Additional information has been requested. A copy of the published article is attached as further documentation of the patient's experience.